PMID- 36259117
OWN - NLM
STAT- MEDLINE
DCOM- 20221020
LR  - 20230118
IS  - 1533-0338 (Electronic)
IS  - 1533-0346 (Print)
IS  - 1533-0338 (Linking)
VI  - 21
DP  - 2022 Jan-Dec
TI  - Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular 
      Carcinoma With Untreatable Progression.
PG  - 15330338221131385
LID - 10.1177/15330338221131385 [doi]
LID - 15330338221131385
AB  - Purpose: The present retrospective study aimed to evaluate the efficacy and 
      safety of camrelizumab addition to transarterial chemoembolization (TACE) in the 
      treatment of hepatocellular carcinoma (HCC) with TACE-related untreatable 
      progression (UP). Methods: Patients with HCC who received addition of 
      camrelizumab due to UP after initial TACE treatment were enrolled at our 
      institution between May 2019 and January 2021. Patients were assessed for tumor 
      response, progression-free survival (PFS), and adverse events (AEs). Risk factors 
      for PFS were evaluated with logistic regression analysis. Results: A total of 41 
      patients were included. The objective response rates (ORR) and disease control 
      rates (DCR) were 24.4% and 61.0% at 2 to 3 months, and 12.2% and 58.5% at 6 
      months, respectively. The median PFS of the patients were 6 months (95% 
      confidence interval [CI]: 3.8 months, 8.2 months). Of the 41 patients, 23 
      received camrelizumab combined with TACE (hereafter, camrelizumab-TACE) on whom 
      52 combined TACE procedures were performed, with a median of 2 procedures (range: 
      1-6) per patient. The remaining 18 patients received camrelizumab alone due to 
      TACE contraindications. Multivariable analysis indicated that camrelizumab-TACE 
      was an independent prognostic factor for PFS. Subgroup analysis showed a median 
      PFS of 8 months in the camrelizumab-TACE group and 3 months in the camrelizumab 
      monotherapy group (P < .001). No treatment-related mortalities occurred. 
      Seventeen patients (41.5%) developed at least 1 type of AE after treatment with 
      camrelizumab, with reactive cutaneous capillary endothelial proliferation (RCCEP) 
      (n = 14, 34.1%) being the most common AE. Conclusion: Addition of camrelizumab to 
      TACE offered an effective and safe treatment for HCC with UP.
FAU - Ren, Yanqiao
AU  - Ren Y
AUID- ORCID: 0000-0001-8086-4527
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan, China.
FAU - Liu, Ziyi
AU  - Liu Z
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan, China.
FAU - Makamure, Joyman
AU  - Makamure J
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan, China.
FAU - Kan, Xuefeng
AU  - Kan X
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan, China.
FAU - Song, Songlin
AU  - Song S
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan, China.
FAU - Liu, Yiming
AU  - Liu Y
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan, China.
FAU - Qian, Kun
AU  - Qian K
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan, China.
FAU - Zheng, Chuansheng
AU  - Zheng C
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan, China.
FAU - Liang, Bin
AU  - Liang B
AD  - Department of Radiology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
AD  - Hubei Provinve Key Laboratory of Molecular Imaging, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Technol Cancer Res Treat
JT  - Technology in cancer research & treatment
JID - 101140941
RN  - 73096E137E (camrelizumab)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/pathology
MH  - *Chemoembolization, Therapeutic/adverse effects/methods
MH  - *Liver Neoplasms/drug therapy
MH  - Retrospective Studies
MH  - Combined Modality Therapy
PMC - PMC9583233
OTO - NOTNLM
OT  - adverse events
OT  - camrelizumab
OT  - progression-free survival
OT  - transarterial chemoembolization
OT  - untreatable progression
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2022/10/20 06:00
MHDA- 2022/10/21 06:00
PMCR- 2022/10/18
CRDT- 2022/10/19 02:23
PHST- 2022/10/19 02:23 [entrez]
PHST- 2022/10/20 06:00 [pubmed]
PHST- 2022/10/21 06:00 [medline]
PHST- 2022/10/18 00:00 [pmc-release]
AID - 10.1177_15330338221131385 [pii]
AID - 10.1177/15330338221131385 [doi]
PST - ppublish
SO  - Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221131385. doi: 
      10.1177/15330338221131385.